Objective To evaluate hypertension and hyperlipidemia management patterns in youth with type 1 diabetes and to assess perceived effectiveness of management strategies and barriers to management.
Conclusions Pediatric diabetes providers commonly defer prescribing antihypertensive and lipid-lowering medications until nonmedication interventions have been ineffective. Most providers describe medications, but not lifestyle interventions, as often effective. Efforts to align clinical practice with clinical guidelines are needed. (J Pediatr 2018; 197:140-6) .
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C ardiovascular disease (CVD) affects persons with type 1 diabetes more frequently, 1 at younger ages, 2 and with greater mortality 3, 4 than persons without type 1 diabetes. Childhood risk factors for CVD such as elevated low-density lipoprotein (LDL) cholesterol or blood pressure (BP) directly relate to early atherosclerosis in young adulthood. 5 Given elevated future CVD risk in children with type 1 diabetes, national guidelines for the management of hypertension and hyperlipidemia recommend more aggressive management in youth with type 1 diabetes than in youth without type 1 diabetes. [6] [7] [8] Previous studies describe a gap between clinical guideline recommendations and clinical management of CVD risk factors in youth with 9, 10 and without type 1 diabetes. [11] [12] [13] However, it is unclear whether differences between clinical guidelines and clinical practice result from an inadvertent gap between intention and actual practice or whether pediatric diabetes providers' treatment paradigms differ from current guidelines. Furthermore, pediatric diabetes providers' perceptions of the effectiveness of management strategies for hypertension and hyperlipidemia and barriers to management have been described incompletely.
By surveying a broad sample of pediatric diabetes providers, we aimed to assess providers' current management strategies for hypertension and hyperlipidemia in youth with type 1 diabetes. We also aimed to describe the perceived effectiveness of various management strategies and the barriers that prevent optimal management of hypertension and hyperlipidemia in youth with type 1 diabetes.
Methods
This provider survey focused on current management practices for hypertension and hyperlipidemia (high LDL) in youth with type 1 diabetes, including strategies for and barriers to optimal management. The survey was developed with an initial literature review, and then questions were drafted by pediatric endocrinologists with input from a multidisciplinary team, including physicians, nurse practitioners, nurse educators, nutritionists, and mental health professionals, all with pediatric type 1 diabetes expertise. Areas surveyed included provider and practice demographic information, workup for hypertension, management recommendations for hypertension and hyperlipidemia, medication use in these conditions, perceived effectiveness of management recommendations, and barriers to treatment in youth with type 1 diabetes and hypertension or hyperlipidemia.
Because we intended to determine how current management compares with commonly referenced guidelines, we specifically queried recommendations and clinical scenarios that related to popular guidelines as well as other clinical scenarios in which medication initiation might reasonably be considered. ). Guideline recommendations for youth with type 1 diabetes are summarized in Table I (available at www.jpeds.com). Cognitive interviewing was conducted with 2 nurse practitioners and 2 physicians, and the survey was revised iteratively in response to their feedback.
The survey initially included 36 main items and then was consolidated to 33 items to ease respondent burden, given the similarity of responses for barriers to hypertension and hyperlipidemia management. A small number of sections used adaptive questioning to reduce the length of the survey and allow respondents to view only relevant questions. Response options included a 5-point Likert scale (never, rarely, sometimes, often, always), forced choice, or multiple responses allowed depending on the question. Questions included an "other" response with the option for free text if respondents chose. The survey required <10 minutes to complete. The full survey is available in the Appendix (available at www.jpeds.com).
The survey was fielded electronically via RedCap (Research Electronic Data Capture) 15 to members of the ADA For survey responses to be included for analysis, demographic questions and the initial question on evaluation of hypertension must have been answered. For analysis, the 5-point Likert scale was consolidated to a 3-point Likert scale. The categories of never and rarely are referred to as "rarely," the category of sometimes remains as "sometimes," and the categories of often and always are referred to as "often." To combine the questions on barriers for hypertension and hyperlipidemia in the 35 individuals who answered the longer survey with separate barrier questions for each condition, responses were maintained for respondents who answered similarly for both conditions (65% of responses). If respondents answered oppositely for hypertension and hyperlipidemia (rarely vs often), then the responses were excluded (7%). If respondents answered either rarely or often for one condition and sometimes for the other condition, then sometimes was kept as the response (28%).
If respondents used the "other" response option and entered free text, the study team categorized and tabulated responses by consensus. Responses that were highly similar to existing response options were recategorized to the existing option. Free text responses written by ≥5% of respondents to a question are reported in the text.
Analyses were conducted in SAS version 9.4 (SAS Institute, Cary, North Carolina). Descriptive analyses were completed for all questions. We conducted c 2 analyses to determine whether differences in provider or medication barriers varied by provider demographic characteristics (provider age, practice setting, years since training completion, sex, and number of patients under provider's care). P < .05 was considered significant.
Results
The survey was fielded to the 1361 members from American Diabetes Association Diabetes in Youth Interest Group, the 1368 Volume 197 • June 2018 members from Pediatric Endocrine Society, and the 754 pediatric providers from T1D Exchange. Of the 260 individuals who opened the survey from the 3 organizations, 16 did not meet inclusion criteria to complete the survey, and 37 were excluded because they provided only demographic information without completing additional survey questions. There was a total of 207 respondents.
Two-thirds of the respondents were female, and 19% were nonwhite. Almost all (95%) resided in the US and were welldistributed throughout different regions (Table II) . A total of 48% of respondents were ≤45 years; 52% were ≥46 years of age.
Respondents were 86% physicians, and the remainder were nurse practitioners, physician's assistants, nurses, and nutritionists (Table II) . Two-thirds of respondents endorsed participating in practice groups that treated at least 500 youth 0-25 years with type 1 diabetes, and 60% cared for >100 youth with type 1 diabetes themselves. About three quarters of respondents practiced in an academic medical center, and 72% focused primarily on clinical practice. The majority (57%) completed their training greater than 10 years ago.
Evaluation strategies for youth with hypertensive-range BPs on 2-3 occasions varied among respondents. Most respondents often obtain laboratory studies (71% often obtain a urinalysis and 65% often obtain a blood urea nitrogen and creatinine). In addition, 7% of respondents wrote in via free text that they would obtain a urine albumin to creatinine ratio, and 15% wrote in that they would refer to a specialist. Many do not perform an extensive workup; 21% often obtain a sleep history, 13% a renal ultrasound scan, 9% 4-extremity BPs, and 7% a cardiac ultrasound scan.
Questions regarding any detailed medical evaluation for hyperlipidemia were not asked, although the survey addressed steps that providers would take before starting a statin, such as repeating a lipid profile, nutritional advice, or improving glycemic control.
Respondents overwhelmingly endorsed lifestyle modification as their initial recommendation for confirmed primary hypertension or hyperlipidemia (LDL ≥130 mg/dL, ≥3.37 mmol/L) in youth with type 1 diabetes. More than 80% of respondents endorsed often providing counseling on healthy eating, increasing physical activity, and losing weight (if patient was overweight/obese) ( Table III) . Respondents also commonly reported recommending improvements to glycemic control (≥95% responded often), repeating BP in other settings (81% responded often), and repeating lipid levels (52% responded often). The majority often referred to a nutritionist; 61% for HTN and 85% for hyperlipidemia. For hypertension, more than one-half of respondents (57%) often initially referred to another specialist, and 27% often started a medication for confirmed primary hypertension. For hyperlipidemia, only 8% often refer to a lipid specialist, and 15% started a medication in their initial management of LDL ≥130 mg/ dL (≥3.37 mmol/L). Twenty-one percent of respondents endorsed never prescribing medication for BP (Table IV) . Among the remaining 79% of prescribers, respondents varied in the circumstances warranting medication to treat BP in a teenager with type 1 diabetes. Of the respondents who did prescribe medication, 73% would prescribe medications for hypertensive-range BP on 2-3 occasions in which lifestyle changes were not effective, and 64% would prescribe medication for hypertensiverange BP on 2-3 occasions with other CVD risk factors present. Fewer would prescribe medication for hypertensive-range BP on 2-3 occasions (without either a trial of lifestyle change or additional CVD risk factors) or for prehypertension (Table IV) .
Sixty-one percent of respondents reported targeting a BP below the hypertensive range for age and sex (Table V) , and 23% of respondents reported targeting a BP below the prehypertensive range (<90th percentile for age, sex, and height) in youth with type 1 diabetes (ADA guidelines, AHA guidelines, and NHLBI guidelines target).
In contrast to the 21% of respondents who reported never prescribing medication for hypertension management, only 8% of respondents endorsed never prescribing medication for high LDL cholesterol. Among those who initiate medication for high LDL cholesterol, 21% would start medication immediately for LDL ≥160 mg/dL (≥4.14 mmol/L), and 76% would start medication for LDL ≥160 (≥4.14 mmol/L) that persists 6-12 months despite nonmedication interventions (lifestyle efforts and/or glycemic management). Approximately onehalf of respondents would start medication for LDL ≥130 (and <160) mg/dL (≥3.37 and <4.14 mmol/L) that persists 6-12 months despite nonmedication intervention with or without additional CVD risk factors, and most do not prescribe medication for LDL <130 mg/dL (3.37 mmol/L) ( Table V) .
More than one-half of respondents (57%) reported titrating medication to a target LDL <100 mg/dL (<2.59 mmol/L, ADA, and AHA target) and 36% reported targeting LDL <130 mg/dL (<3.37 mmol/L, NHLBI target). Almost all providers (97%) prescribing lipid-lowering medications reported choosing a statin.
Of the possible recommendations provided, the majority of respondents endorsed medications as most likely to be often effective (68% responded often effective for HTN and 69% for hyperlipidemia) ( Table III) . The next most effective recommendation was referral to a specialist (68% responded often effective for HTN and 38% for hyperlipidemia). However, few respondents reported that advice to improve glycemic control, recommendations to lose weight, or referral to a dietician were often effective (9%-17%; Table III) . Recommendations for general healthy eating, increasing physical activity, increasing dietary fiber, increasing omega-3 fatty acids, or limiting salt were each judged to be often effective by less than 10% of respondents.
There were a number of perceived barriers to effective hypertension or hyperlipidemia management. Respondents endorsed insufficient patient support for lifestyle change, lack of patient motivation to control BP and/or lipid levels, and lack of patient confidence to follow through on lifestyle changes as common patient-related barriers to HTN and/or lipid management (endorsed "often" a barrier by 69%, 62%, and 61% of respondents, respectively, Table VI [available at www.jpeds.com]). In reflecting on their own barriers to providing care to patients with HTN and/or hyperlipidemia, providers most commonly endorsed insufficient patient education materials, medical visits were too short to focus on diabetes AND HTN and/or hyperlipidemia, and limited provider training on HTN and/or hyperlipidemia management (endorsed "often" by 40%, 39%, and 33%, respectively).
Provider endorsement of barriers differed by age and experience. Providers who completed training <10 years ago vs ≥10 years ago more commonly endorsed lack of familiarity with practice guidelines (22% vs 7%, P = .03), lack of expertise prescribing medication (35% vs 13%, P = .005), and concerns about patient adherence (44% vs 24%, P = .02) as often barriers to managing HTN or hyperlipidemia. Similarly, providers ≤45 years old vs >45 years old more commonly endorsed lack of familiarity with practice guidelines (21% vs 7%, P = .04) and lack of expertise prescribing medication (30% vs 16%, P = .06) as often barriers to managing HTN or hyperlipidemia. Providers who practiced outside of an academic setting more frequently cited lack of specialists for referral as a barrier (23% vs 5%, P = .007). There were no differences according to number of patients cared for or according to sex.
Discussion
Although CVD is recognized as the leading cause of morbidity and premature mortality in type 1 diabetes, addressing CVD risk factors in young persons with type 1 diabetes is an understudied area. This study has evaluated provider practices in managing CVD risk factors in type 1 diabetes. Although most respondents report lifestyle counseling for initial management of both hypertension and hyperlipidemia, they described this counseling as often ineffective. Respondents reported more frequent referrals for hypertension and more frequently initiating medications for hyperlipidemia.
Studies document widespread underdiagnosis of pediatric hypertension in general 11 and in youth with type 1 diabetes in particular. 9, 16 Even when provided with the diagnosis of "confirmed primary hypertension" as stated in our survey, providers infrequently followed national evaluation and recommendation guidelines. (However, just greater than one-half of respondents refer to hypertension specialists, who may then follow recommended evaluations and treatments, although this was not assessed.) Pediatric diabetes providers often did not perform extensive diagnostic evaluations for secondary hypertension or to assess end organ damage. Between survey fielding and manuscript publication, new pediatric hypertension guidelines were published by the American Association for Pediatrics that reduced the need to perform such evaluations. 14 Thus, clinical practice anticipated guideline revision in this circumstance.
Pediatric diabetes specialists responding to this survey described treatment for hypertension that was less aggressive than commonly referenced guidelines. For example, only 15% of providers (excluding those who would never prescribe) would prescribe medication in all situations recommended by ADA guidelines. As AHA and NHLBI guidelines differ from ADA and are less aggressive, about 30%-50% of respondents would be in compliance with these recommendations. ADA, AHA, and NHLBI guidelines recommend a BP target below the prehypertensive range for youth with diabetes; however, most pediatric diabetes providers are less aggressive, targeting below the hypertensive range rather than the prehypertensive range when titrating antihypertensive medications. Although pediatric diabetes providers are presumably comfortable with prescribing angiotensin-converting enzyme inhibitors or angiotensin receptor blocks to treat elevated urinary albumin excretion, 17 this familiarity has not transferred to comfort with treating elevated BP using these same classes of medications.
Studies also document the widespread undertreatment of lipid disorders in youth in general 12 and youth with type 1 diabetes. 10, 16 In our survey, 44% of respondents (excluding those who never prescribe) would start lipid-lowering medications as recommended by ADA guidelines, and only 3% would start medication in all circumstances recommended by AHA guidelines, which are more aggressive (NHLBI guidelines are intermediate). Although rates of medication use endorsed by our respondents may be below recommended guidelines, this contrasts with pediatric primary care providers, who overwhelmingly endorsed discomfort with lipid disorder management (83%) and who disagreed with using lipid-lowering medication in youth (57%). 18 However, comfort and experience among pediatric diabetes providers may vary geographically and reticence to prescribe may not be limited to the US. In a recent survey of members of the Association of Children's Diabetes Clinicians of England, Northern Ireland, and Wales only 14% of clinicians had started a statin in the past 5 years. 19 Providers most strongly endorsed patient-related barriers such as lack of support, motivation, or self-efficacy (confidence) rather than barriers within their practice. A survey of management practices in pediatric type 2 diabetes similarly described difficulties in making lifestyle changes in patients as the most commonly cited barrier for both hypertension and lipid management. 20 Only 18% of respondents reported that insufficient evidence for hypertension and/or lipid management in youth was often a barrier. This contrasts with a systematic review reporting limited evidence as to when to initiate lipid-lowering therapy or what cholesterol level to target in THE JOURNAL OF PEDIATRICS • www.jpeds.com Volume 197 pediatric patients. 21 Younger (≤45 years), less-experienced (<10 years in practice) providers were more likely to cite lack of expertise and/or lack of familiarity with practice guidelines as barriers suggesting education and training opportunities for this demographic.
There are limitations to this survey study. First, the survey had a limited response rate. Part of this low response rate may have resulted from providers receiving this survey from 2-3 organizations due to membership in multiple organizations. In 2011, there were an estimated 893 clinically practicing boardcertified pediatric endocrinologists in the US. 22 Although our 207 respondents included some non-MDs (11%) and non-US providers (5%), we captured a respectable proportion of pediatric diabetes physicians practicing in the US. Other surveys have yielded similar response rates. 23 The low response could signify nonresponse bias among providers unlikely to manage CVD risk factors, creating an overestimation of provider management and adherence with guidelines (as diabetes providers with limited knowledge or experience may have been less likely to complete the survey). Second, our survey assessed provider-reported management decisions in response to diagnosed hypertension and hyperlipidemia; it did not discuss provider diagnosis of these conditions. Additional studies might consider assessing healthcare provider criteria for diagnosing hypertension, prehypertension, and hyperlipidemia. Third, our survey captured provider report, which may differ from actual practice. Finally, the relatively low adherence to practice guidelines for evaluation of hypertension may have related to the high rates (57%) of referrals.
Our findings suggest providers inconsistently follow practice guidelines, especially with regard to medication initiation and titration. There is greater comfort with managing hyperlipidemia compared with hypertension among pediatric diabetes providers. We speculate that providers may have greater confidence with lipid measurements than BP measurements, which can be highly variable and impacted by measurement technique (manual vs automated methods). Although electronic medical records can flag elevated BP and lipid values, it is unclear how often electronic decision support for management of either or both hypertension and hyperlipidemia is available in current EMRs for teens with type 1 diabetes. Differences among clinical guidelines may contribute to poor adherence with the recommendations. To improve hypertension and lipid management for youth with type 1 diabetes, guidelines should be harmonized, and the resulting product should be explained clearly at professional conferences, through virtual education efforts, and incorporated into electronic decision support. Finally, the frequent endorsement of patient support, motivation, and self-efficacy as barriers to hypertension and hyperlipidemia management suggests the need for interventions to target these areas to motivate behavior change. With dedicated efforts, the management of hypertension and hyperlipidemia in youth with type 1 diabetes will improve. ■ In general, the long-term safety of low-dose MTX is excellent, with very rare serious adverse events. However, the report by Milunsky et al reminds us of one of the most serious adverse events, the development of congenital malformations when MTX is given during pregnancy. They reviewed a case report and 7 others from the literature of maternal ingestion of MTX during the first trimester of pregnancy (between weeks 4 and 12) to induce (in these cases unsuccessful) abortion. The doses given, between 10 and 29 mg (median 12 mg), are in the usual range of the onceweekly doses used today for inflammatory diseases. In all cases, the fetuses developed severe congenital malformations. The most common were skull bone deficits and deformities, but other malformations included anencephaly, hydrocephalus, and other skeletal malformations (especially in the ribs, fingers/toes, and talipes equinovarus). Lowset and malformed ears, cleft lip, hypertelorism, and micrognathia were common findings. Four of the fetuses were later aborted, and of those born, 2 died shortly after birth and 2 survived. The height and weight of the surviving child described by the authors remained well below the third percentile.
MTX remains a category X pregnancy risk medication. Therefore, it is imperative of us who prescribe MTX (and their primary physicians!) to discuss and counsel on the issue of pregnancy prevention/birth control in patients with the potential to conceive at the time of starting therapy and to frequently review this issue during follow-up visits. The frequency of reviewing this issue should be at least annually and much more frequently in patients engaging in risk-taking behaviors. 
